A prospective cohort study of the efficacy and safety of BOTOX-A versus surgery for the treatment of Acute Concomitant Esotropia (AACE)

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068735

Enrollment

Unknown

Registered

2023-02-28

Start date

2023-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Concomitant Esotropia (AACE)

Interventions

BOTOX group (botox injection in medial rectus):None

sugery group (strabismus surgery):None

Eligibility

Sex/Gender

All

Age

10 Years to 40 Years

Inclusion criteria

Inclusion criteria: Meet the AACE diagnostic criteria with strabismus > 20PD 1,Acute onset, acquired esotropia, sudden diplopia (ipsilateral horizontal diplopia) 2,Intermittent or constant esotropia 3,normal motility, having equal deviation in all directions and no signs of paralysis

Exclusion criteria

Exclusion criteria: 1,accommadative spasm, convergent spasm and accommodative esotropia 2,Vertical unconcomitant ( AV pattern) 3,Abnormal oblique muscle function 4,limiting factors in the rectus muscle tested by forced duction test 5,nystagmus 6, amblyopia 7,anisometropia 8,Organic diseases of the anterior segment and posterior segment, abnormal craniofacial development affecting the orbit, and obvious nervous system abnormalities 9,Preterm term, low-body weight infants 10,Nervous and psychiatric system abnormalities and taking psychotropic drugs

Design outcomes

Primary

Measure	Time frame
deviation;fusional range;binocular vision;	—

Countries

China

Contacts

Public Contactli yueping,zhang wei

TIANJIN EYE HOSPITAL

leeyueping@aliyun.com+86 13820365230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026